přejít na obsah
Price indexes for clinical trial research : a feasibility study Náhled dokumentu
ZavřítNáhled dokumentu
Probíhá kontrola...

Price indexes for clinical trial research : a feasibility study

Autor Ernst R Berndt; Iain Cockburn; National Bureau of Economic Research.
Vydavatel: Cambridge, Mass. : National Bureau of Economic Research, 2013.
Edice: Working paper series (National Bureau of Economic Research), no. 18918.
Vydání/formát:   e-kniha : Document : EnglishZobrazit všechny vydání a formáty
Databáze:WorldCat
Shrnutí:
We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from MediData Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose  Přečíst více...
Hodnocení:

(ještě nehodnoceno) 0 zobrazit recenze - Buďte první.

Předmětová hesla:
Více podobných

 

Najít online exemplář

Vyhledat exemplář v knihovně

&AllPage.SpinnerRetrieving; Vyhledávání knihoven, které vlastní tento dokument...

Detaily

Typ materiálu: Document, Internetový zdroj
Typ dokumentu: Internet Resource, Computer File
Všichni autoři/tvůrci: Ernst R Berndt; Iain Cockburn; National Bureau of Economic Research.
OCLC číslo: 835500084
Poznámky: Title from http://www.nber.org/papers/18918 viewed April 4, 2013.
"March 2013."
Popis: 1 online resource (35 p.) : ill.
Název edice: Working paper series (National Bureau of Economic Research), no. 18918.
Odpovědnost: Ernst R. Berndt, Iain M. Cockburn.

Anotace:

We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from MediData Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose only 2.2-fold. Most of the disparity appears to be attributable to changes in the nature and organization of clinical trials: during this period the average number of patients per site fell substantially while "site work effort" more than doubled. After controlling for these changes in the characteristics of investigator agreements using a variety of methods based on hedonic regressions, we find that the estimated rate of inflation in clinical trials costs tracks the BDRPI very closely. Results from this study suggest that it should be feasible for statistical agencies to develop a producer price index for this type of R&D activity, contributing to broader efforts to develop a deflator for contracted R&D services.

Recenze

Recenze vložené uživatelem
Nahrávání recenzí GoodReads...
Přebírání recenzí DOGO books...

Štítky

Buďte první.
Potvrdit tento požadavek

Tento dokument jste si již vyžádali. Prosím vyberte Ok pokud chcete přesto v žádance pokračovat.

Propojená data


<http://www.worldcat.org/oclc/835500084>
library:oclcnum"835500084"
library:placeOfPublication
library:placeOfPublication
owl:sameAs<info:oclcnum/835500084>
rdf:typeschema:Book
schema:about
<http://id.loc.gov/authorities/subjects/sh2007003908>
rdf:typeschema:Intangible
schema:name"Research and development projects--Costs--Econometric models."
schema:about
schema:bookFormatschema:EBook
schema:contributor
schema:contributor
schema:creator
schema:datePublished"2013"
schema:description"We estimate hedonic price indexes for clinical trial research, an important component of biomedical R&D, using a large sample of agreements between trial sponsors and clinical investigators obtained from MediData Solutions Worldwide Inc. Nominal prices measured as total grant cost per patient rose by a factor of 4.5 between 1989 and 2011, while the NIH Biomedical R&D Price Index (BRDPI) focused on input costs rose only 2.2-fold. Most of the disparity appears to be attributable to changes in the nature and organization of clinical trials: during this period the average number of patients per site fell substantially while "site work effort" more than doubled. After controlling for these changes in the characteristics of investigator agreements using a variety of methods based on hedonic regressions, we find that the estimated rate of inflation in clinical trials costs tracks the BDRPI very closely. Results from this study suggest that it should be feasible for statistical agencies to develop a producer price index for this type of R&D activity, contributing to broader efforts to develop a deflator for contracted R&D services."
schema:exampleOfWork<http://worldcat.org/entity/work/id/1218425129>
schema:inLanguage"en"
schema:name"Price indexes for clinical trial research a feasibility study"
schema:publisher
schema:url
schema:url<http://www.nber.org/papers/w18918>

Content-negotiable representations

Zavřít okno

Prosím přihlaste se do WorldCat 

Nemáte účet? Můžete si jednoduše vytvořit bezplatný účet.